Structured evidence table for Nac Respiratory Support Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Nac Respiratory Support Meta-Analysis | Beyond established risk factors such as smoking and exposure to pollutants increasing evidence emphasizes the role of oxidative stress (OS) in COPD pathophysiology. | 1 | López-Denis M (2026) | Antioxidants as Therapeutic Tools in the Management of COPD: A Systematic Review with Meta-Analysis. |
| Nac Respiratory Support Meta-Analysis | N-acetylcysteine-based interventions were associated with a significant reduction in exacerbation risk (risk ratio 0.80; 95% confidence interval 0.66-0.98), corresponding to a 20% relative reduction. | 1 | López-Denis M (2026) | Antioxidants as Therapeutic Tools in the Management of COPD: A Systematic Review with Meta-Analysis. |
| Nac Respiratory Support Meta-Analysis | Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. | 1 | López-Denis M (2026) | Antioxidants as Therapeutic Tools in the Management of COPD: A Systematic Review with Meta-Analysis. |
| Nac Respiratory Support Meta-Analysis | This document consolidates existing evidence to this effect, and adds insights from practicing clinicians to guide about use of NAC in clinical practice. | 2 | Barne M (2026) | N-acetylcysteine: evidence based consensus document on the therapeutic advantages in respiratory diseases (NECTAR). |
| Nac Respiratory Support Meta-Analysis | Conclusion This consensus underscores the role of NAC in chronic respiratory diseases beyond its mucolytic properties and reiterates that NAC's antioxidant, anti-inflammatory, immunomodulatory and anti-biofilm properties provide significant clinical utility. | 2 | Barne M (2026) | N-acetylcysteine: evidence based consensus document on the therapeutic advantages in respiratory diseases (NECTAR). |
| Nac Respiratory Support Meta-Analysis | While promising for TB and respiratory infections, further evidence is required. | 2 | Barne M (2026) | N-acetylcysteine: evidence based consensus document on the therapeutic advantages in respiratory diseases (NECTAR). |
| Nac Respiratory Support Meta-Analysis | Background N-acetylcysteine (NAC) is a key precursor of glutathione (GSH), the lung's principal antioxidant. | 2 | Barne M (2026) | N-acetylcysteine: evidence based consensus document on the therapeutic advantages in respiratory diseases (NECTAR). |
Source documents